MD Pharma SA
The score of MD Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +94 % Total assets +25 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
MD Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jul 2026
- Year ended 31 Dec 2024filed on 30 Jul 2025
- Year ended 31 Dec 2023filed on 25 Jul 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 20 Jul 2022
MD Pharma's financial analysis
- Solvency67.5%sector median: 58.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of MD Pharma
MD Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0667.779.672
- VAT number
- BE0667779672
- Peppol
- Registered · 0208:0667779672 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 16 Dec 2016
- Registered office
- 9051 Ghent
- Latest accounts
- 2025 · filed on 30 Jul 2026
- Activity
- Leasing of intellectual property and similar products, except copyrighted works (NACE 77400)
MD Pharma (SA) has been based in Ghent since 2016, active in: leasing of intellectual property and similar products, except copyrighted works. For 2025, it reports a net profit of 257,132 € and equity of €1.79m; its revenue is not published. Its solvency stands at 67.5%, above the median of its sector (58.9%).
Companies similar to MD Pharma
Companies in the same business, of comparable size and area, outside its group.
- Abak Invest Leasing of intellectual property and similar products, except copyrighted works Merelbeke-Melle · balance sheet €2.34m
- Skol International Development Leasing of intellectual property and similar products, except copyrighted works Watermael-Boitsfort · balance sheet €9.34m
- Molipoly Leasing of intellectual property and similar products, except copyrighted works Herent · balance sheet 469,424 €
- Base Holding Leasing of intellectual property and similar products, except copyrighted works Saint-Gilles · balance sheet 763,584 €
- Beisol Pharma Tienen Leasing of intellectual property and similar products, except copyrighted works Lubbeek · balance sheet 121,648 €
- Puressentiel TM Leasing of intellectual property and similar products, except copyrighted works Ixelles · balance sheet €4.01m
- Taster BE Leasing of intellectual property and similar products, except copyrighted works Brussels · balance sheet €1.67m
- Foodip Leasing of intellectual property and similar products, except copyrighted works Zedelgem · balance sheet €4.49m
Frequently asked questions about MD Pharma
What is the revenue of MD Pharma?
MD Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of MD Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0667779672 for MD Pharma, if the company is VAT-registered. Its company number (CBE) is 0667.779.672.
Where is the registered office of MD Pharma?
According to the CBE register, the registered office of MD Pharma is in 9051 Ghent.
What is the equity of MD Pharma?
At the close of the 2025 financial year, the equity of MD Pharma amounts to 1,791,157 €, a solvency of 67.5% of total assets.
Who manages MD Pharma?
The register lists 4 active mandates at MD Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of MD Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →